Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs Healthicare

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Healthicare head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 283 · Grade C

Healthicare

Visit Healthicare Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 64 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

That doesn't make Healthicare a bad call — it's best for readers who want an itemized program quote and can confirm the actual prescription, applicable billing agreement and clinical costs. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
46
Supply Reliability
95
69
Transparency
90
72
Access Breadth
93
62
Clinical Oversight
92
72
Track Record
88
68
CoreAge RxBrief Score 94 · 64Healthicare

Price, coverage & the tracker

CoreAge RxHealthicare
Brief Score94/100 (A)64/100 (C)
Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

$126 monthly or $321.30 quarterly

Quarterly advertised equivalent $107.10/month. Published prices exclude California.

Exact semaglutide formulation and applicable agreement unconfirmed; older recurring-membership terms differ from no-membership marketing.

Full price details

Semaglutide program listed; exact formulation and complete selected agreement unknown; $126 billed monthly or $321.30 every three months ($107.10/month equivalent), advertised outside California

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

$144 monthly or $367.20 quarterly

Quarterly advertised equivalent $122.40/month; named compounded program. Published prices exclude California.

Applicable agreement and refund milestones unconfirmed; do not equate monthly billing with the terms’ twenty-eight-to-thirty-day cycle.

Full price details

Compounded tirzepatide program listed; complete selected agreement unknown; $144 billed monthly or $367.20 every three months ($122.40/month equivalent), advertised outside California

CoverageUS only; restrictions by state, confirmed at intakePublished medication prices apply to U.S. states except California; clinician and pharmacy eligibility still require confirmation
Brand-name accessNot confirmedBranded comparisons and a separate Wegovy link do not establish the current branded terms of the reviewed semaglutide/tirzepatide programs.
Oral / sublingualInjection onlyUnconfirmed
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.

Healthicare: Published outside California: semaglutide $126 monthly/$321.30 quarterly; tirzepatide $144 monthly/$367.20 quarterly. Exact selected agreement and semaglutide formulation require confirmation.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.